🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

17,82 USD

Máx. histórico

178,74

2145 días

Split 1:6 del 12/07/2012

Caída desde máximo

-90,03%

Rango 52 semanas

14,68 – 24,68

Variación hoy

+1,42%

Cierre anterior

17,57

Rango de hoy

17,52 – 18,77

Volumen hoy

2.596.193

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,43%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 18 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
03/02/2014 24,16 24,49 22,60 22,83 -6,36% 7,82% 1.612.800
31/01/2014 24,52 25,36 24,16 24,38 -2,52% 4,89% 937.600
30/01/2014 24,94 25,55 24,37 25,01 +3,01% 4,73% 762.800
29/01/2014 24,98 25,24 23,96 24,28 -3,46% 5,12% 884.600
28/01/2014 24,10 25,30 24,00 25,15 +3,88% 5,39% 1.123.100
27/01/2014 24,65 24,74 22,90 24,21 -4,83% 7,46% 2.036.800
24/01/2014 27,23 27,49 24,80 25,44 -7,69% 9,88% 2.146.200
23/01/2014 27,23 28,16 26,65 27,56 +0,73% 5,55% 1.208.400
22/01/2014 28,17 28,22 27,05 27,36 -2,36% 4,15% 1.242.400
21/01/2014 28,39 29,40 27,60 28,02 +4,63% 6,34% 4.104.400
17/01/2014 27,37 28,50 26,15 26,78 -4,36% 8,59% 3.421.100
16/01/2014 23,01 28,80 22,62 28,00 +40,14% 26,86% 14.412.500
15/01/2014 20,39 20,50 19,79 19,98 -2,01% 3,48% 1.550.200
14/01/2014 20,00 20,50 19,63 20,39 +1,54% 4,35% 1.208.000
13/01/2014 19,86 21,28 19,50 20,08 +3,35% 8,96% 2.305.300
10/01/2014 19,33 20,02 19,05 19,43 +0,99% 5,02% 1.498.200
09/01/2014 18,49 19,35 18,25 19,24 +4,85% 5,95% 1.530.300
08/01/2014 17,69 18,50 17,50 18,35 +2,46% 5,65% 1.655.200
07/01/2014 18,76 18,91 17,83 17,91 -4,58% 5,76% 1.680.000
06/01/2014 19,21 19,60 17,76 18,77 -8,17% 9,58% 4.226.000
03/01/2014 20,56 20,75 20,25 20,44 -0,68% 2,43% 917.200
02/01/2014 20,26 20,90 20,01 20,58 +1,03% 4,39% 851.300
31/12/2013 20,93 21,06 20,23 20,37 -1,97% 3,97% 1.553.200
30/12/2013 20,19 21,48 19,92 20,78 +4,95% 7,73% 2.253.700
27/12/2013 20,08 20,08 19,52 19,80 -1,00% 2,79% 666.000
26/12/2013 20,62 20,62 19,69 20,00 -0,05% 4,51% 1.110.800
24/12/2013 19,91 20,18 19,66 20,01 +0,20% 2,61% 528.500
23/12/2013 20,50 20,87 19,25 19,97 +2,15% 7,90% 1.788.600
20/12/2013 18,55 19,71 18,47 19,55 +5,90% 6,68% 2.918.200
19/12/2013 18,56 19,06 18,21 18,46 -1,91% 4,58% 1.366.300